|
End-of-day quote
Taipei Exchange
28/08/2026
|
5-day change | 1st Jan Change | ||
| 22.60 TWD | -0.66% |
|
0.00% | -12.23% |
| 08-13 | GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-03 | GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021 | CI |
Company Valuation: GlycoNex Incorporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2,798 | 2,885 | 3,261 | 3,232 | 2,711 | 2,786 |
| Change | - | 3.11% | 13.02% | -0.89% | -16.13% | 2.79% |
| Enterprise Value (EV) 1 | 2,320 | 2,554 | 2,806 | 2,532 | 2,269 | 2,567 |
| Change | - | 10.1% | 9.87% | -9.76% | -10.42% | 13.14% |
| P/E | -15.7x | -16.6x | -13.8x | -18x | -11.8x | -11.9x |
| PBR | 1.81x | 2.12x | 2.26x | 2.53x | 2.59x | 2.95x |
| PEG | - | 5.84x | -0.6x | 0.7x | -0.4x | -6.45x |
| Capitalization / Revenue | 6,205x | 527x | 108x | 1,271x | 184x | 73.6x |
| EV / Revenue | 5,143x | 466x | 93.3x | 996x | 154x | 67.8x |
| EV / EBITDA | -13.8x | -15.5x | -14.1x | -11.1x | -10.7x | -12x |
| EV / EBIT | -10.8x | -13.1x | -11.7x | -9.74x | -9.22x | -10.3x |
| EV / FCF | -26x | -26.4x | -25.2x | 28.1x | -12.4x | -8.11x |
| FCF Yield | -3.84% | -3.78% | -3.97% | 3.55% | -8.09% | -12.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.832 | -1.78 | -2.21 | -1.654 | -2.123 | -2.162 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.451 | 5.475 | 30.08 | 2.542 | 14.7 | 37.86 |
| EBITDA 1 | -167.5 | -164.9 | -199 | -228.7 | -211.7 | -214.4 |
| EBIT 1 | -214.1 | -194.9 | -238.9 | -259.9 | -246.1 | -249.8 |
| Net income 1 | -162.7 | -172.5 | -219.8 | -178.4 | -229.7 | -235.2 |
| Net Debt 1 | -479 | -331.6 | -455.1 | -699.8 | -442.1 | -219.7 |
| Reference price 2 | 28.70 | 29.60 | 30.45 | 29.75 | 25.05 | 25.75 |
| Nbr of stocks (in thousands) | 97,508 | 97,482 | 107,098 | 108,640 | 108,208 | 108,208 |
| Announcement Date | 24/03/21 | 28/03/22 | 31/03/23 | 19/03/24 | 14/03/25 | 24/03/26 |
1TWD in Million2TWD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 80.31M | |
| 34.28x | 6.11x | 18.18x | 0.94% | 50.47B | |
| -21.19x | 258.61x | -22.63x | -.--% | 44.56B | |
| 33.71x | 3.27x | 14.1x | -.--% | 43.08B | |
| 48.04x | 5.57x | 30.46x | -.--% | 41.7B | |
| 28.96x | 8.75x | 22.11x | 0.4% | 33.21B | |
| 34.16x | 5.6x | 25.43x | -.--% | 16.77B | |
| 24.12x | 2.1x | 9.08x | 1.12% | 14.58B | |
| 77.98x | 4.1x | 15.89x | -.--% | 13.92B | |
| Average | 32.51x | 36.76x | 14.08x | 0.31% | 28.71B | |
| Weighted average by Cap. | 27.93x | 49.08x | 12.78x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4168 Stock
- Valuation GlycoNex Incorporation
Select your edition
All financial news and data tailored to specific country editions
